failed previous hiv therapies. in 2008, johnson & johnson acquired mentor corporation for $1 billion and merge its operations into ethicon. in 2009, the company acquired healthmedia, later renamed to health & wellness solutions and the human performance institute. in october 2010, j&j acquired crucell for $2.4 billion. the subsidiary operates as the centre for vaccines, within johnson & johnson pharmaceuticals business group. in 2012, alex gorsky became chairman and ceo of johnson & johnson. in november 2015, biosense webster, inc. acquired coherex medical inc. expanding the company’s range of treatment options for patients with atrial fibrillation. in 2017, johnson & johnson acquired abbott medical optics from abbott laboratories for $4.325 billion, adding the new division into johnson & johnson vision care, inc. in 2017. the same year, johnson & johnson acquired actelion in a $30 billion deal, the largest ever purchase by the company. after the purchase, johnson & johnson spun off actelion’s research and development unit, into a separate legal entity. in july 2017, johnson & johnson vision care, inc acquired tearscience. in september 2017, the company acquired subscription-based contact lens startup sightbox. in september of the same year johnson & johnson medical gmbh acquired emerging implant technologies gmbh, manufacturer of 3d-printed titanium interbody implants for spinal fusion surgery. in march 2019, the fda approved esketamine for the treatment of severe depression, which is marketed as spravato by janssen pharmaceuticals. in 2019, johnson & johnson announced the release of photochromic contact lenses. the lenses adjust to sunlight and help eyes recover from bright light exposure faster. the lenses contain a photochromic additive that adapts visible light amounts filtered to the eyes and are the first to use such additives. in november 2020, johnson & johnson acquired momenta pharmaceuticals for $6.5 billion. in january 2022, joaquin duato became ceo of johnson & johnson. in november 2022, johnson & johnson announced that it would acquire abiomed inc for $16.6 billion. the deal closed on december 22. coronavirus (covid-19) response johnson & johnson committed over $1 billion toward the development of a not-for-profit covid-19 vaccine in partnership with the biomedical advanced research and development authority (barda) office of the assistant secretary for preparedness and response (aspr) at the u.s. department of health and human services (hhs). paul stoffels of johnson & johnson said, "in order to go fast, the people of johnson & johnson are committed to do this and all together we say we're going to do this not for profit. that's the fastest and the best way to find all the collaborations in the world to make this happen so we commit to bring this at a not-for-profit level." janssen vaccines, in partnership with beth israel deaconess medical center (bidmc), is responsible for developing the vaccine candidate, based on the same technology used to make its ebola vaccine. the vaccine candidate is expected to enter phase 1 human clinical study in september 2020. demand for the product tylenol surged two to four times normal levels in march 2020. in response, the company increased production globally. for example, the tylenol plant in puerto rico ran 24 hours a day, seven days a week. in response to the shortage of ventilators, ethicon, with prisma health, made and distributed the vesper ventilator expansion splitter, which uses 3d printing technology, to allow one ventilator to support two patients. johnson & johnson johnson & johnson johnson & johnson consumer inc. (consumer healthcare division) dabao cosmetics co. johnson & johnson consumer france sas groupe vendome sa lge performance systems, inc. healthmedia, inc. vogue international llc tristrata inc. neostrata company, inc. zarbee's, inc. medical devices division biosense webster (acq 1997) coherex medical, inc. (acq 2015) depuy synthes (acq 1998) codman & shurteff, inc. (acq 1965) micrus endovascular pulsar vascular inc. neuravi depuy mitek, inc. depuy orthopaedics, inc. biomedical enterprises, inc. depuy spine, inc interventional spine, inc. depuy synthes products, inc sentio, llc olive medical corporation advanced sterilization products (divested 2018) apsis sas gloster europe orthotaxy johnson & johnson medical gmbh surgical process institute emerging implant technologies gmbh (acq. 2017) ethicon, inc. (est. 1944 as ethicon suture laboratories) g. f. merson ltd (acq. 1947) mentor (acq. 2008) omrix biopharmaceuticals, inc. acclarent neuwave medical, inc torax medical johnson & johnson (china) investment ltd guangzhou bioseal biotechnology co., ltd. ethicon endo-surgery surgrx, inc. sterilmed, inc. megadyne medical products, inc. auris health inc verb surgical inc abiomed inc (acq. pending) impella cardiosystems ag (acq. 2005) ecp entwicklungsgesellschaft mbh (acq. 2014) aachen innovative solution gmbh precardia (acq. 2021) breethe (acq. 2020) janssen diagnostics bvba johnson & johnson vision care, inc. vistakon abbott medical optics (acq. 2017) tearscience sightbox pharmaceuticals division janssen pharmaceutica (acq. 1961) cilag (acq. 1959) j b chemicals & pharmaceuticals limited (otc division) covagen corimmun gmbh aragon pharmaceuticals, inc. alios biopharma, inc. novira therapeutics, inc. actelion (acq. 2017) momenta pharmaceuticals (acq. 2020) janssen r&d llc janssen healthcare innovation janssen biotech, inc. ortho biotech inc. ortho-clinical diagnostics, inc. johnson & johnson nordic ab amic ab kite merger sub, inc. cougar biotechnology, inc. respivert benevir biopharm, inc. janssen therapeutics janssen diagnostics janssen scientific affairs crucell (acq. 2010) ortho-mcneil-janssen pharmaceutical services, inc. janssen-ortho ortho-mcneil mcneil consumer healthcare (acq. 1959) janssen covid-19 vaccine main article: janssen covid-19 vaccine in june 2020, johnson & johnson and the national institute of allergy and infectious diseases (niaid) confirmed its intention to start a clinical trials of j&j's vaccine in september 2020, with the possibility of phase 1/2a human clinical trials starting at an accelerated pace in the second half of july. on august 5, 2020, the us government agreed to pay more than $1 billion to johnson and johnson (medical device company) for the production of 100 million doses of covid-19 vaccine. as part of the agreed-upon deal, the u.s. can order up to 200 million additional doses of sars-cov-2 vaccine. in september 2020, johnson & johnson started its 60,000-person phase 3 adenovirus-based vaccine trial. the trial was paused on october 12, 2020, because a volunteer became ill, but the company said it found no evidence that the vaccine had caused the illness and announced on october 23, 2020, that it would resume the trial. in april 2021, the company reported that its covid-19 vaccine achieved $100 million sales in the first quarter, accounting for less than 1% of its total revenue. business sectors the company's business is divided into three major business sectors: pharmaceuticals, medtech, and consumer health. in 2020, these segments contributed 55%, 28%, and 17%, respectively, of the company's total revenues. johnson & johnson innovation, llc (jji) is a subsidiary of johnson & johnson. jji focuses on early-stage, life science, and technology innovations to advance the company’s research and development pipeline. jji provides startups with sourcing, infrastructure, and capital equipment at jlabs, financing & venture capital at jjdc, inc., and collaborations leading to the potential development of medical device technologies, pharmaceuticals, and therapeutics. there are 4 jji innovation centers located in london, shanghai, boston (cambridge), and the san francisco bay area. there are 13 jlabs incubators located in the bay area (san francisco and south san francisco), belgium (beerse), boston (cambridge and lowell), houston (tmc), new york, philadelphia, san diego, shanghai, toronto, and washington d.c. johnson & johnson business sectors pharmaceuticalsmedtech consumer health immunologycardiovascular & metabolic diseasepulmonary hypertensioninfectious diseases & vaccinesneuroscienceoncologyinterventional solutionsorthopaedicssurgery (general & advanced)vision baby careoral careover the counter medicinesskin healthwomen's healthwound care pharmaceuticals the pharmaceutical segment is focused on six therapeutic areas: immunology (rheumatoid arthritis, inflammatory bowel disease and psoriasis); infectious diseases (hiv/aids); neuroscience (mood disorders, neurodegenerative disorders and schizophrenia); oncology (prostate cancer and hematologic malignancies); cardiovascular, metabolism, & retina (thrombosis and diabetes), and pulmonary hypertension (pulmonary arterial hypertension). medtech the cardiovascular & specialty solutions group includes electrophysiology products that diagnose and treat cardiac arrhythmias; devices used in the endovascular treatment of hemorrhagic and ischemic stroke; solutions that focus on breast reconstruction and aesthetics, and ear, nose and throat procedures. the orthopaedics portfolio is composed of specialties including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery and sports medicine, in addition to the vely digital surgery portfolio. the surgery portfolio includes advanced surgical innovations and solutions such as sutures, staplers, energy devices, and advanced hemostats along with interventional ablation, surgical robotics, and digital solutions. the johnson & johnson vision portfolio includes contact lens, intraocular lens, automated treatment for dry eye, and four brands of laser vision correction systems. consumer health the consumer health business sector includes a broad range of products focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women's health, and wound care markets. it comprises skin health/beauty, self-care, and essential health categories. the skin health/beauty category includes personalized skin health assessments, treatments for acne, eczema and aging signs, and cleansers, moisturizers, and sunscreens. the self-care category includes medicines for pain relief, smoking cessation, allergy, anti-diarrheal, antacids, nasal decongestants, and cough and colds. the essential health category includes products for wound care, oral care, baby care and women's health. in september 2022, johnson & johnson chose kenvue as the new name for its consumer health business. kenvue was spun off and went public through an ipo in may 2023, with j&j maintaining a controlling stake of around 91 percent. finance for the fiscal year 2022, johnson & johnson reported earnings of $17.9 billion, with an annual revenue of $94.94 billion, an increase of 1.25% over the previous fiscal cycle. johnson & johnson's shares traded at over $175 per share, and its market capitalization was valued at over $439.8 billion in september 2022. year revenuein million us$ net incomein million us$ employees 2005 50,514 10,060 115,600 2006 53,324 11,053 122,200 2007 61,095 10,576 119,200 2008 63,747 12,949 118,700 2009 61,897 12,266 115,500 2010 61,587 13,334 114,000 2011 65,030 9,672 117,900 2012 67,224 10,853 127,600 2013 71,312 13,831 128,100 2014 74,331 16,323 126,500 2015 70,074 15,409 127,100 2016 71,890 16,540 126,400 2017 76,450 1,300 155,000 2018 81,581 15,297 134,000 2019 82,059 15,119 132,200 2020 82,584 14,714 134,500 2021 93,775 20,878 141,700 2022 94,943 17,941 155,800 corporate governance the current members of the board of directors of johnson & johnson for 2023 are: mary c. beckerle; d scott davis; ian e. l. davis; jennifer a doudna; alex gorsky; marillyn a. hewson; hubert joly; mark b. mcclellan; anne m. mulcahy; a. eugene washington; mark a. weinberger; nadja y. west; and darius adamczyk. the current members of the executive committee of johnson & johnson are: joaquin duato; vanessa broadhurst; peter fasolo; liz forminard; william n. hait; ashley mcevoy; thibaut mongon; james swanson; jennifer taubert; kathy wengel; joseph j. wolk. joaquin duato is chairman and chief executive officer. chairmen robert wood johnson i (1887–1910) james wood johnson (1910–1932) robert wood johnson ii (1932–1963) philip b. hofmann (1963–1973) richard b. sellars (1973–1976) james e. burke (1976–1989) ralph s. larsen (1989–2002) william c. weldon (2002–2012) alex gorsky (2012–2022) joaquin duato (2023-present) headquarters and the new brunswick gentrification the company has historically been located on the delaware and raritan canal in new brunswick. the company considered moving its headquarters out of new brunswick in the 1960s but decided to stay in the town after city officials promised to revitalize downtown new brunswick by demolishing old buildings and constructing new ones. while new brunswick lost many historic structures, including the early home of rutgers university, and most of its historic commercial waterfront to the redevelopment effort, the gentrification did attract people back to new brunswick. johnson & johnson hired henry n. cobb from pei cobb freed & partners to design its new headquarters. johnson and johnson plaza, in a park across the railroad tracks from the older portion of the headquarters, is one of tallest buildings in new brunswick. the stretch of delaware and raritan canal by the company's headquarters was replaced by a stretch of route 18 in the late 1970s, after a lengthy dispute. in 2002, the company released its plan of setting up asia-pacific information technology headquarters in new south wales within five years. environmental record johnson & johnson has set several positive goals to keep the company environmentally friendly and was ranked third among the united states's largest companies in newsweek's "green rankings". some examples are the reduction in water use, waste, and energy use and an increased level of transparency. johnson & johnson agreed to change its packaging of plastic bottles used in the manufacturing process, switching